Provider: View Press Release
Type: Link
Title: Media Update: Positive data from two Phase 3 Dupixent® (dupilumab) trials in prurigo nodularis published in Nature Medicine
Description: Positive data from two Phase 3 Dupixent® (dupilumab) trials in prurigo nodularis published in Nature Medicine Paris and Tarrytown, N.Y. May 8, 2023....
Provider: View Press Release
Type: Link
Title: Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
Description: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting HARMONIE Phase 3b data reinforce nirsevimab’s...
Provider: View Press Release
Type: Link
Title: Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
Description: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting HARMONIE Phase 3b data reinforce nirsevimab’s...
Provider: View Press Release
Type: Link
Title: Press Release: Sanofi completes acquisition of Provention Bio, Inc.
Description: Sanofi completes acquisition of Provention Bio, Inc. Paris, April 27 2023. Sanofi announced today the completion of its acquisition of Provention...
Provider: View Press Release
Type: Link
Title: Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC
Description: Strong Q1 growth driven by Specialty Care, Vaccines and CHC Paris, April 27, 2023 Q1 2023 sales growth of 5.5% at CER and business EPS(1) growth of...
Provider: View Press Release
Type: Link
Title: Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
Description: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine Dupixent...